PLENARY LECTURE

Omar Abudayyeh, PhD

Assistant Professor at Harvard Medical School / Brigham and Women's Hospital / MGB Gene and Cell Therapy Institute

Programmable Technologies for Engineering Biology

PLENARY LECTURE

Palani Palaniappan, PhD

Chief Technical Operations & Quality Officer @ Flagship Pioneering

Practical Paths for Advancing Cell & Gene Therapy Development: Navigating Headwinds and Risks Towards Resilient Translation

 PLENARY LECTURE

Panteli Theocharous, FIBMS, M.S., PhD, FRCPath

CEO @ VectorGen

Designing Cell & Gene Therapy Backwards From the Patient-Clinical, Operational, and Financing Lessons

 Prof. Mimoun Azzouz, PhD

School of Medicine & Population Health, Chair of Translational Neuroscience, Director of GTIMC @ University of Sheffield, UK

Gene Therapy Ecosystem at The University of Sheffield 

Eva Andres-Mateos, PhD

Associated VP Preclinical Development Gene Therapy @ Eli Lilly

Translational sciences for GT/clinical data - talk title TBA

Shashi Ramaiah, PhD

President, Founder, and CEO @ SPECCRO, Inc.

Derisking Gene Therapy (AAV): Translational Strategies and Emerging Tools to Navigate Safety Risks

Brian Furmanski, PhD

Chief Regulatory Officer @ Kriya Therapeutics

The Path to First-in-Human: Regulatory and Strategic Considerations for CGT IND Submissions 

Jeff Moffit, PhD, DABT

Head of Toxicology & Translational Development @ BMS - Orbital Therapeutics

BMS-986553 - A Novel In Vivo Anti-CD19 CAR Circular RNA Formulated in Targeted LNP for the Treatment of B-cell-driven Autoimmune Diseases

Amy Rosenberg, M.D.

Senior Director, Bioanalytical Sciences @ Regeneron

Success of CAR-T Cells in Treatment of Autoimmunity: Broader Application to Disease Treatment & Prevention Including Immunogenicity of Therapeutic Proteins

Matt Silva, PhD

CEO @ EMIT Imaging

Cryo-Fluorescence Tomography: Transformative 3D Imaging for Gene & Cell Therapy 

Aman Singh, PhD

Group Director - Clinical Pharmacology & Pharmacometrics @ Johnson & Johnson

Quantitative Pharmacology of Ex Vivo and In Vivo Cell Therapies in Autoimmune Conditions

Karan Sharma, 

CEO @ Boston BioProducts, Inc.

On-Demand Customization of Buffer Solutions for Cell Culture and Bioprocessing

Joleen White, PhD

Senior Consultant @ BioData Solutions

Immunogenicity in Cell and Gene Therapy: Risk Assessment, Assays, and IVDR Implications 

Mandy Xie, PhD

Executive Director, Head of Analytical Development & Attribute Science @ Bristol Myers Squibb

Manufacturing Reality Check: CMC Drivers of Cost, Speed, and Consistency in Cell Therapy

Amanda Placone, PhD

Genetic Medicine Business Development & Strategy @ Eli Lilly and Company

Panel Discussion: Stepping Back From Cell & Gene Therapy: CMC Challenges and Investment Reality

Abood Okal, PhD

Director, Immuno-Oncology & Cellular Therapy Translational Research @ BMS

Leveraging Translational Learnings from Liso-cel in NHL to Inform CAR-T Development

Sreethu Sankar, 

Senior Product Manager @Proteintech Group Inc.

Protein Engineering Strategies to Support Cell and Gene Therapy Reagent Ecosystem

Dariush Mohammadyani, PhD

VP, Commercial @ Differentia Bio

Mechanistic Modeling for Gene Therapy Empowered by AI